Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Archive for August, 2012

Cadence Pharmaceuticals: Ofirmev Launch Has Gained Traction; Reiterate Buy

Investment Overview and Opinion I reiterate my Buy recommendation on Cadence. The Ofirmev launch has now gained traction as just reported 2Q, 2012 revenues of $11.1 million exceededguidance of $10.0 to $10.4 million. Management guidance for 3Q, 2012 of $13.7 to $14.2 million is better than the existing Street consensus of $13.6million. The metrics for […]

Bristol-Myers Squibb: Side Effect Issue with Hepatitis C Drug Creates a Buying Opportunity (BMY, $32.55)

Side Effect Issue Leads to Sharp Price Drop Bristol-Myers disclosed on August 1, 2012 that it has suspended a phase II trial in hepatitis C in which BMS-986094, its nucleotide polymerase inhibitor, was being studied in combination with daclatasvir, its NS5a inhibitor. BMS-986094 has been broadly viewed as the cornerstone of BMY’s effort to develop […]

Bristol-Myers Squibb: Best Positioned for Growth of the Four Big US Pharma Companies

Bristol-Myers (BMY), Eli Lilly (LLY), Merck (MRK) and Pfizer (PFE) were out of favor for many years based on concerns about pricing and attempts to reduce drug utilization brought on by world economic pressures, lack of visibility on new products and pending patent cliffs. Each has patent expirations on major products that will essentially result […]